This study investigated the efficacy and toxicity associated with consolidation chemotherapy using paclitaxel and carboplatin after concurrent chemoradiation (CCR) in cervical cancer patients.
From a total of 37 patients, 19 with International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IIA cervical cancer (group 1) underwent surgery followed by consolidation chemotherapy after CCR, and 18 with stage IIB-IVA disease (group 2) received consolidation chemotherapy after primary CCR. Three cycles of chemotherapy using paclitaxel (135 mg/m2) and carboplatin (AUC 5.0) were administered every 3 weeks for CCR therapy, and three cycles of consolidation chemotherapy using paclitaxel (175 mg/m2) and carboplatin (AUC 5.0) were used every 3 weeks after CCR.
The complete and partial response rates were 77.8% and 22.2% in group 2. Moreover, the 3-year progression-free and overall survival rates were 62.7% and 90.9% in group 1, and 51.9% and 60% in group 2, respectively. The most common grade 3 or 4 hematologic toxicities observed were leukopenia (group 1, 10.5%; group 2, 13.0%) and neutropenia (group 1, 7.0%; group 2, 14.8%), and grade 3 or 4 diarrhea (group 1, 1.8%) and febrile illness (group 2, 1.9%) were the most frequently observed non-hematologic toxicities. When we compared these results with previous reports, consolidation chemotherapy after CCR using paclitaxel and carboplatin revealed a relatively lower complete response rate (77.8% vs. 87-100%, respectively) and shorter progression-free survival (51.9-62.7% vs. 81-86%, respectively) and overall survival (60-90.9% vs. 81-95%, respectively) in spite of similar toxicity findings.
Due to low efficacy results, consolidation chemotherapy using paclitaxel and carboplatin after CCR is not a feasible treatment regimen for high-risk early-stage or locally advanced cervical cancer.
The application of radiation therapy (RT) has been reportedly extended for use in treatment of International Federation of Gynecology and Obstetrics (FIGO) stage IB1 to IVA cervical cancers [
Since 2000, cisplatin-based CCR has been found to be the most effective treatment for patients with high-risk early-stage or locally advanced cervical cancer [
Combination therapy using paclitaxel and carboplatin is the standard chemotherapeutic regimen producing acceptable toxicity in treating patients with epithelial ovarian cancer [
Thus, we hypothesized that consolidation chemotherapy using paclitaxel and carboplatin would improve tumor response and survival in patients. We therefore performed a phase II clinical trial of consolidation chemotherapy using paclitaxel and carboplatin after adjuvant CCR for subjects with high-risk early-stage cervical cancer who had undergone primary surgery, or after primary CCR for those with locally-advanced disease.
After designing this clinical trial, we registered it in advance with the US National Institutes of Health (NIH) (registration no., NCT-00591656 and -00592059). The current study took place at Seoul National University Hospital (SNUH) and the clinical protocol was approved by the SNUH Institutional Review Board. Patients were enrolled after providing their written informed consent.
The current study was performed with two groups in order to evaluate the efficacy and toxicity of consolidation chemotherapy using paclitaxel and carboplatin following CCR as follows: group 1 consisted of patients with stage IB1 to IIA cervical cancer who underwent type II (n=17) or III (n=2) hysterectomy with pelvic or para-aortic lymphadenectomy, and received 3 cycles of consolidation chemotherapy after adjuvant CCR based on histologic results such as one or more high-risk factors (positive resection margin, parametrial invasion or lymph node metastasis); group 2 included patients with locally advanced cervical cancer (stage IIB to IVA) who received primary CCR followed by 3 cycles of consolidation chemotherapy.
The eligibility criteria were as follows: age > 20 years, Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1, life expectancy > 6 months, and normal hematologic, renal and liver function. We excluded patients with a history of other malignancies, prior chemotherapy or RT, or underlying diseases which might influence clinical outcomes.
External-beam radiotherapy (EBRT) with concurrent chemotherapy was performed with patients in both groups. EBRT was delivered to the whole pelvis using 6 or 10 megavoltage photons through either the parallel-opposed (antero-posterior/postero-anterior) ports, or the four-field box technique. The upper and lower borders of the EBRT ports were at the L5-S1 junction and at least 2 cm below the vault of the vaginal cuff or the gross tumor, respectively. The lateral edges were set to 1.5 cm lateral to the bony pelvis. The anterior and posterior borders were the anterior aspect of the symphysis pubis and the S2-S3 junction, respectively. The median radiation dose of 50.4 Gy (range, 50.0 to 61.2 Gy) was delivered in 1.8-2.0 Gy fractions once daily, 5 days per week.
If there were gross para-aortic lesions over the T12-L1 junction, the field of the EBRT irradiation was continuous with extension to the T12-L1 junction or higher. The median radiation doses delivered to para-aortic lesions were 45 Gy (range, 45.0 to 61.2 Gy) in group 1 patients, with histological confirmation of para-aortic lymph node metastasis, and 60 Gy (range, 45.0 to 63.0 Gy) in all group 2 patients. Intracavitary irradiation (ICR) was administered to all patients in group 2. ICR was delivered using the Fletcher-Suit unit with 137Cs sources with a median dose of 31.4 Gy (range, 22.0 to 34.6 Gy).
Chemotherapy consisted of three cycles of paclitaxel (135 mg/m2) and carboplatin (AUC 5.0, Calvert's formula) every 3 weeks during CCR. After CCR, three cycles of consolidation chemotherapy using paclitaxel (175 mg/m2) and carboplatin (AUC 5.0, Calvert's formula) were administered every 3 weeks. When chemotherapy was delayed due to the appearance of grade 3 or 4 toxicity, we re-evaluated the toxicity after one week. And if resolved, we administered a 75% dose of paclitaxel and carboplatin. Although our study design disqualified patients if chemotherapy was delayed more than 3 weeks, no patients were excluded.
Tumor response and disease recurrence were investigated by physical examination and imaging studies including chest X-ray, computed tomography and positron emission tomography according to response evaluation in solid tumors (RECIST) criteria [
Toxicity was evaluated using Common Terminology Criteria for Adverse Events (CTCAE) ver. 3.0. PFS and OS were defined as the time elapsed from the date of diagnosis to the date of clinically proven recurrence, and the time elapsed from the date of diagnosis to the date of cancer-related death or the end of the current study, respectively.
Patient characteristics, tumor response and toxicity were evaluated using descriptive summary statistics. PFS and OS were calculated by the Kaplan-Meier method. The 95% confidential intervals (CIs) for the estimated response and survival rate were calculated using binominal distribution. Statistical analyses were performed using SPSS ver. 17.0 (SPSS Inc., Chicago, IL). A p-value <0.05 was considered statistically significant.
A total of 37 patients were enrolled between November 2006 and December 2009. Of the total, 19 (group 1) underwent primary surgery plus adjuvant CCR followed by 3 cycles of consolidation chemotherapy, whereas 18 patients (group 2) received primary CCR followed by 3 cycles of consolidation chemotherapy using paclitaxel and carboplatin. Clinical characteristics of the study participants are depicted in
In group 1, the most common grade 3 or 4 hematologic toxicities observed were leukopenia (total, 10.5%; CCR, 7.0%; consolidation chemotherapy, 14.0%) and neutropenia (total, 7.0%; CCR, 3.5%; consolidation chemotherapy, 10.5%). Six patients (31.6%) received a 75% dose of paclitaxel and carboplatin with a mean one-week delay. However, all patients recovered by conservative management or the administration of granulocyte colony-stimulating factor (G-CSF) without life-threatening complications. Furthermore, the most frequent grade 3 or 4 non-hematologic toxicity observed was diarrhea (total, 1.8%; CCR, 3.5%; consolidation chemotherapy, 0%), and one patient (5.3%) presented grade 3 genitourinary toxicity as cystitis with hematuria, a late RT-related toxicity (
Subsequent to consolidation chemotherapy after post-surgery CCR, 7 patients (36.8%) showed disease recurrence at lymph nodes (n=3), bone (n=1), lung (n=1), vaginal vault (n=1) and peritoneum seeding with lymph nodes (n=1). The 3-year PFS and OS rates were 62.7% (95% CI, 26.7 to 40.7) and 90.9% (95% CI, 42.3 to 47.1), respectively (
In group 2, the most frequent grade 3 or 4 hematologic toxicities observed were neutropenia (total, 14.8%; CCR, 16.7%; consolidation chemotherapy, 13.0%) and leukopenia (total, 13.0%; CCR, 16.7%; consolidation chemotherapy, 9.2%). Eight patients (44.4%) received a 75% dose of paclitaxel and carboplatin with a mean two-week delay. These toxicities were improved by supportive care or the administration of G-CSF without any treatment-related deaths. The most common grade 3 or 4 non-hematologic toxicity observed was febrile illness (total, 1.9%; CCR, 3.7%; consolidation chemotherapy, 0%) and one patient (5.6%) showed grade 4 gastrointestinal toxicity consisting of proctitis with perforation as a late RT-related toxicity (
Subsequent to consolidation chemotherapy after CCR, 14 (77.8%) and 4 patients (22.2%) demonstrated CR and PR, whereas 8 patients (44.4%) showed disease recurrence at lymph nodes (n=5), bone (n=1), peritoneum (n=1) and cervix with lymph nodes (n=1). The 3-year PFS and OS rates were 51.9% (95% CI, 25.0 to 42.5) and 60% (95% CI, 31.6 to 46.5), respectively (
The aim of this phase II clinical trial was to evaluate the efficacy and toxicity of 3 cycles of consolidation chemotherapy after CCR using paclitaxel and carboplatin in patients with stage IB1 to IIA cervical cancer who had undergone primary surgery, or those with stage IIB to IVA cervical cancer. Chemotherapy regimens using paclitaxel and carboplatin have been focused on by previous studies, whereby taxanes and platinum agents have been shown to have different molecular targets with synergistic anti-cancer effects and acceptable toxicities [
In the current study, we found that consolidation chemotherapy after CCR using paclitaxel and carboplatin failed to improve PFS and OS as compared to CCR-only in patients with high-risk early-stage cervical cancer who underwent surgical treatment (3-year PFS, 62.7% vs. 88.2%, respectively; 3-year OS, 90.9% vs. 97.3%, respectively) [
In order to identify the efficacy and toxicity results of the use of paclitaxel and carboplatin in consolidation chemotherapy after CCR in treating cervical cancer, we compared our current results with those of relevant previous reports where the efficacy and toxicity of consolidation chemotherapy using platinum-based drugs after CCR had been investigated (
The current study had two limitations. First, despite a few retrospective studies where its efficacy was demonstrated, the efficacy of CCR using paclitaxel and carboplatin has not been established in clinical trials for high-risk early-stage or locally advanced cervical cancer. Second, the number of enrolled patients was small which may have resulted in study data bias. In spite of these limitations, our current study indicated that, due to relatively low efficacy, consolidation chemotherapy using paclitaxel and carboplatin after CCR is not recommendable for patients with high-risk early-stage or locally advanced cervical cancer.
However, the merits of the use of paclitaxel with carboplatin include reduced nephrotoxicity, requiring no hydration, relatively brief administration time in the outpatient setting, and a lower rate of nausea and vomiting, which increases the compliance to chemotherapy dosing [
Consolidation chemotherapy using dose-dense combination of paclitaxel and carboplatin after CCR every 3 weeks is not feasible to treat high-risk early-stage or locally advanced cervical cancer because of low efficacy. However, a promising combination of weekly paclitaxel and carboplatin is expected to be worthy of the need for additional clinical trials to approve high efficacy and low toxicity.
This research was supported by Seoul National University Hospital (04-2008-036).
Conflict of interest relevant to this article was not reported.
Efficacy of paclitaxel and carboplatin as consolidation chemotherapy after concurrent chemoradiation (CCR) in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IIA (group 1) and stage IIB-IVA (group 2) cervical cancer; (A) progression-free survival and (B) overall survival curves for 19 patients who underwent primary surgery followed by three cycles of consolidation chemotheray after CCR (group 1) and 18 patients who received primary CCR followed by three cycles of consolidation chemotherapy (group 2).
Patient characteristics (n=37)
Characteristics | Group 1 (n=19) | Group 2 (n=18) |
---|---|---|
Median age (range, yr) | 48 (24-72) | 52 (37-74) |
Menopause | 8 (42.1) | 13 (72.2) |
ECOG performance status | ||
0 | 17 (89.5) | 16 (88.9) |
1 | 2 (10.5) | 2 (11.1) |
FIGO stage | ||
IB1 | 13 (68.4) | - |
IB2 | 2 (10.5) | - |
IIA | 4 (21.1) | - |
IIB | - | 12 (66.7) |
IIIA | - | 2 (11.1) |
IVA | - | 4 (22.2) |
Median tumor size (range, cm) | 4.0 (2.1-9.0) | 4.2 (2.5-8.9) |
Histology | ||
Squamous carcinoma | 15 (78.9) | 17 (94.4) |
Adenocarcinoma | 2 (10.5) | 1 (5.6) |
Adenosquamous carcinoma | 1 (5.3) | 0 (0) |
Mixed carcinoma | 1 (5.3) | 0 (0) |
Lymph-vascular space invasion | ||
No | 14 (73.7) | - |
Yes | 5 (26.3) | - |
Stromal invasion | ||
<1/2 | 17 (89.5) | - |
≥1/2 | 2 (10.5) | - |
Parametrial invasion | ||
No | 13 (68.4) | - |
Yes | 6 (31.6) | - |
Lymph node metastasis | ||
No | 16 (84.2) | 17 (94.4) |
Yes | 3 (15.8) | 1 (5.6) |
Positive resection margin | ||
No | 19 (100) | - |
Yes | 0 (0) | - |
Values are presented as number (%). ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynecology and Obstetrics. a)Lymph node metastasis was evaluated by imaging studies.
Grade 3 or 4 acute and late toxicities
Acute toxicities |
Late radiation therapy-related toxicities (n=37) |
||||||
---|---|---|---|---|---|---|---|
Toxicities | No. of cycles (%) |
Sites | No. of patients (%) |
||||
Group 1 |
Group 2 |
Group 1 (n=19) | Group 2 (n=18) | ||||
CCR (57 cycles) | Consolidation (57 cycles) | CCR (54 cycles) | Consolidation (54 cycles) | ||||
Hematological | 8 (14.0) | 16 (28.0) | 19 (35.2) | 16 (29.6) | Gastrointestinal | 0 (0) | 1 (5.6) |
Anemia | 2 (3.5) | 2 (3.5) | 1 (1.8) | 4 (7.4) | Genitourinary | 1 (5.3) | 0 (0) |
Leukopenia | 4 (7.0) | 8 (14.0) | 9 (16.7) | 5 (9.2) | |||
Neutropenia | 2 (3.5) | 6 (10.5) | 9 (16.7) | 7 (13.0) | |||
Thrombocytopenia | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||
Non-hematological | 3 (5.3) | 0 (0) | 3 (5.6) | 0 (0) | |||
Febrile illness | 0 (0) | 0 (0) | 2 (3.7) | 0 (0) | |||
Nausea/Vomiting | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||
Diarrhea | 2 (3.5) | 0 (0) | 1 (1.9) | 0 (0) | |||
Constipation | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||
Peripheral neuropathy | 1 (1.8) | 0 (0) | 0 (0) | 0 (0) |
CCR, concurrent chemoradiation.
Summary of relevant studies for investigating the efficacy and toxicity of consolidation chemotherapy after CCR in cervical cancer
Study | Study design | No. of patients | FIGO stage | Histology | Primary treatment | RT | Concurrent chemotherapy | Consolidation chemotherapy | CR (%) | Grade 3-4 common toxicity (%) | Survival (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
Peters et al. [18] | Phase III | 127 | IA-IIA | SC |
Surgery | EBRT | 2 cycles of F (1 g/m2)/P (70 mg/m2) every 3 wk | 2 cycles of F (1 g/m2)/P(70 mg/m2) every 3 wk | - | Neutropenia(9.0) |
81 (4 yr OS) |
Vrdoljak et al. [7] | Phase II | 44 | IB2-IVA | SC | CCR | EBRT+LDR | 2 cycles of I (2 g/m2)/P (75 mg/m2) every 3 wk | 2 cycles of I (2 g/m2)/P (75 mg/m2) every 3 wk | 100 | Leukopenia (36) |
84 (PFS) |
Nausea (8.0) |
91 (OS) | ||||||||||
Vomiting (8.0) |
|||||||||||
Proctitis (6.8) |
|||||||||||
Cystitis (4.5) |
|||||||||||
R-V fistula (4.5) |
|||||||||||
Ureteral obstruction (4.5) |
|||||||||||
V-V fistula (2.3) |
|||||||||||
Chung et al. [8] | Phase I/II | 63 | IIB-IVA | SC | CCR | EBRT+HDR | 2 cycles of P (50-80 mg/m2) every 4 wk | 2 cycles of F (600-800 mg/m2)/P (60-80 mg/m2) every 4 wk | - | Proctitis (3.0) |
81-86 (3 yr PFS) |
AC | Cystitis (2.0) |
81 (3 yr OS) | |||||||||
ASC | |||||||||||
Choi et al. [9] | Phase II | 32 | IB2-IVA | SC | CCR | EBRT+HDR | 3 cycles of F (1 g/m2)/P (60 mg/m2) every 3 wk | 3 cycles of F (1 g/m2)/P (60 mg/m2) every 3 wk | 87 | Neutropenia (7.5) |
83 (3 yr PFS) |
AC | Anemia (7.0) |
91 (3 yr OS) | |||||||||
ASC | Nausea/Vomiting (7.0) |
||||||||||
Zhang et al. [19] | Phase II | 34 | IIB-IIIB | SC | CCR | EBRT+HDR | 6 cycles of T (35 mg/m2)/N (20 mg/m2) every 1 wk | 4 cycles of T (135 mg/m2)/N (60 mg/m2) every 3 wk | 88 | Leukopenia (10.9) |
82 (2 yr PFS) |
Neutropenia (9.2) |
95 (2 yr OS) | ||||||||||
Nausea/Vomiting (2.0) |
|||||||||||
Proctitis (5.9) |
|||||||||||
Cystitis (3.0) |
|||||||||||
Kim et al. |
Phase II | 10 | IB1-IIA | Surgery | EBRT+LDR | 3 cycles of T (135 mg/m2) /C (AUC 5.0) every 3 wk | 3 cycles of T (175 mg/m2)/C (AUC 5.0) every 3 wk | - | Leukopenia (10.5) |
62.7 ( 3yr PFS) | |
Neutropenia (7.0) |
90.9 (3 yr OS) | ||||||||||
SC | Diarrhea (1.8) |
||||||||||
AC | Cystitis (5.3) |
||||||||||
14 | IB1-IIA | ASC | CCR | 77.8 | Leukopenia (13.0) |
51.9 (3 yr PFS) | |||||
Mixed | Neutropenia (14.8) |
60 (3 yr OS) | |||||||||
Febrile illness (1.9) |
|||||||||||
Proctitis (5.6) |
CCR, concurrent chemoradiation; FIGO, International Federation of Gynecology and Obstetrics; RT, radiation therapy; CR, complete response; SC, squamous cell carcinoma; AC, adenocarcinoma; ASC, adenosquamous carcinoma; EBRT, external beam radiation therapy; F, 5-fluorouracil; P, cisplatin; PFS, progression-free survival; OS, overall survival; I, ifosfamide; LDR, low dose rate intracavitary irradiation; R-V, rectovaginal; V-V, vesicovaginal; HDR, high dose rate intracavitary brachytherapy; T, paclitaxel; N, nedaplatin; C, carboplatin. a)Number of events per patients, b)Number of events per cycles of chemotherapy, c)The current study.